Indivior Pharmaceuticals (INDV) Total Non-Current Liabilities (2021 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Total Non-Current Liabilities of $1.3 billion for Q1 2026, down 4.62% year-over-year from $1.4 billion in Q1 2025, and up 4.17% quarter-over-quarter from $1.2 billion in Q4 2025.
Indivior Pharmaceuticals (INDV) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $1.3 billion for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 4.62% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (down 4.62% YoY), while the FY2025 annual figure was $1.2 billion, down 3.03% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $1.3 billion, up from $1.2 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $1.7 billion in Q2 2025, with the low at $649.0 million in Q4 2023.
- The 5-year median for Total Non-Current Liabilities is $1.3 billion (2024), against an average of $1.2 billion.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities dropped 15.27% in 2022, then soared 98.31% in 2024.
- Indivior Pharmaceuticals' Total Non-Current Liabilities stood at $699.0 million in 2022, then fell by 7.15% to $649.0 million in 2023, then jumped by 98.31% to $1.3 billion in 2024, then fell by 3.03% to $1.2 billion in 2025, then climbed by 4.17% to $1.3 billion in 2026.
- Business Quant data shows INDV's Total Non-Current Liabilities at $1.3 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Indivior Pharmaceuticals | 4.51 Bn | 4.29 Bn | 294.00 Mn | 1.40 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.40 Bn |
| Mar 31, 2026 | 1.30 Bn |
| Dec 31, 2025 | 1.25 Bn |
| Sep 30, 2025 | 1.32 Bn |
| Jun 30, 2025 | 1.69 Bn |
| Mar 31, 2025 | 1.36 Bn |
| Dec 31, 2024 | 1.29 Bn |
| Dec 31, 2023 | 649.00 Mn |
| Dec 31, 2022 | 699.00 Mn |
| Dec 31, 2021 | 825.00 Mn |